


## AMENDMENTS TO THE CLAIMS

Kindly cancel claims 1-22 and add new claims 23-37 as provided in the following Claims Listing.

### Claims Listing:

Claims 1-22 (Cancelled).

23. (New) A method for the treatment of a pathology associated with the constriction of smooth muscle cells in a subject in need thereof, said method comprising administering to said subject a compound of formula (Ia):



in which:

- R<sub>1</sub> and R<sub>2</sub> represent a hydrogen atom,
- R<sub>5</sub> represents a hydrogen atom, or a linear or substituted alkyl group with 1 to 10 carbon atoms, in particular a butyl group, or an ester of formula COOR' in which R' represents a linear or substituted alkyl group with 1 to 10 carbon atoms,
- Y represents an -OH, -SH, or -NH<sub>2</sub> group,
- R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, and R<sub>10</sub> represent a hydrogen atom, or at least one of R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, or R<sub>10</sub> represents a halogen atom selected from the group comprising a chlorine, bromine or

fluorine atom, and

- X represents an anion.

24. (New) The method of claim 23, wherein said pathology is a vascular disorder.

25. (New) The method of claim 24, wherein said pathology is arterial hypertension.

26. (New) The method of claim 23, wherein said pathology is associated with bronchoconstriction.

27. (New) The method of claim 26, wherein said pathology is asthma.


28. (New) The method of claim 23, wherein X is chloride, bromide, or perchlorate.

29. (New) The method of claim 23, wherein R<sub>5</sub> is a butyl group.


30. (New) The method of claim 23, wherein R' is an ethyl group.

31. (New) The method of claim 23, wherein said compound of formula (Ia) is selected from the following compounds:


**compound 13 (MPB-01)**




**compound 11 (MPB-26)**




**compound 14 (MPB-02)**




**compound 15 (MPB-03)**




**compound 16**




**compound 17**




**compound 24**




**compound 12 (MPB-05)**




**compound 18 (MPB-06)**




**compound 19 (MPB-07)**




**compound 20 (MPB-08)**




**compound 21 (MPB-27)**




**compound 25 (MPB-30)**




**compound 26 (MPB-29)**




**compound 27 (MPB-32)**




**compound MPB-91**




**compound MPB 73**




**compound MPB 75**




**compound MPB 86**




**compound MPB 77**




**compound MPB 87**




**compound MPB 88**



**compound MPB 102**




**compound MPB 103**




32. (New) The method of claim 23, wherein said compound of formula (Ia) is MPB-07 of the following formula:

**compound 19 (MPB-07)**




33. (New) The method of claim 23, wherein said compound of formula (Ia) is MPB-91 of the following formula:

**compound MPB-91**




34. (New) A compound selected from:


**compound MPB 73**




**compound MPB 75**




**compound MPB 86**




**compound MPB 77**



**compound MPB 87**




**compound MPB 88**




35. (New) A compound selected from:

**compound MPB 102**



**compound MPB 103**



36. (New) A pharmaceutical composition comprising a compound of claim 34 in combination with a pharmaceutically acceptable carrier.

37. (New) A pharmaceutical composition comprising a compound of claim 35 in combination with a pharmaceutically acceptable carrier.